
Quarterly ResultNov 17, 2026, 04:30 PM
Lantern Pharma Q3 Net Income $696K; Forms AI Subsidiary
AI Summary
Lantern Pharma Inc. (LTRN) filed its Form 10-Q for the period ending September 30, 2026. The company reported a net income of $696,615 for the three months ended September 30, 2026, a significant improvement from a net loss of $4,177,423 in the same period last year. For the nine months ended September 30, 2026, the net loss was $9,704,680, compared to a net loss of $13,045,221 in the prior year. The company also announced the formation of Open Medicine AI Inc. as a wholly-owned subsidiary to commercialize its AI co-scientist platform, with plans for it to become a newly listed company.
Key Highlights
- Lantern Pharma reported net income of $696,615 for Q3 2026, compared to a net loss of $4,177,423 in Q3 2025.
- For the nine months ended Sept 30, 2026, net loss was $9,704,680, an improvement from $13,045,221 in the prior year.
- Total assets decreased to $8,524,529 as of Sept 30, 2026, from $11,035,811 as of Dec 31, 2025.
- Total liabilities increased to $7,114,276 as of Sept 30, 2026, from $4,501,587 as of Dec 31, 2025.
- Stockholders' equity decreased to $1,410,253 as of Sept 30, 2026, from $6,534,224 as of Dec 31, 2025.
- Formed Open Medicine AI Inc. as a wholly-owned subsidiary to commercialize its AI co-scientist platform.
- Cash and cash equivalents increased to $7,615,813 as of Sept 30, 2026, from $4,422,838 as of Dec 31, 2025.
Price Impact
More from LTRN